Vallabhaneni S, Adusumalli S, Wu J, Groeneveld PW, Gerson J, O'Quinn RP. Cardiotoxicity from bruton tyrosine kinase inhibitors (BTKi)-an analysis of an administrative health claims database. , Cardiooncology: 2024
Yegya-Raman N, Ho Lee S, Friedes C, Wang X, Iocolano M, Kegelman TP, Duan L, Li B, Berlin E, Kim KN, Doucette A, Denduluri S, Levin WP, Cengel KA, Cohen RB, Langer CJ, Kevin Teo BK, Zou W, O'Quinn RP, Deasy JO, Bradley JD, Sun L, Ky B, Xiao Y, Feigenberg SJ. Cardiac radiation dose is associated with inferior survival but not cardiac events in patients with locally advanced non-small cell lung cancer in the era of immune checkpoint inhibitor consolidation. , Radiother Oncol. 2024: 2024
Yegya-Raman N, Kegelman TP, Ho Lee S, Kallan MJ, Kim KN, Natarajan J, Deek MP, Zou W, O'Reilly SE, Zhang Z, Levin W, Cengel K, Kao G, Cohen RB, Sun LL, Langer CJ, Aggarwal C, Singh AP, O'Quinn R, Ky B, Apte A, Deasy J, Xiao Y, Berman AT, Jabbour SK, Feigenberg SJ Death without progression as an endpoint to describe cardiac radiation effects in locally advanced non-small cell lung cancer. , Clin Transl Radiat Oncol.: 2023
Fanaroff AC, Coratti S, Halaby R, Sanghavi M, O'Quinn RP, Krishnan S, Glassberg H, Bajaj A, Adusumalli S, Chokshi N, Patel MS. Feasibility and outcomes from using a commitment devices and text message reminders to increase adherence to time-restricted eating: A randomized trial. , Am Heart J. : 2023
O’Quinn R, Corry AJ, Bajwa N, et al. Longitudinal review of cardiac events with acalabrutinib in the treatment of chronic lymphocytic leukemia (CLL) using data from 3 phase 3 randomized controlled trials. , Presented at: 2023 International Workshop on CLL; October 6-9, 2023; Boston, Massachusetts. Abstract 1552457.: 2023
Vidula, MK, O’Quinn R, Sanghavi M, Litt H, Han Y, Bravo PE. Not All That Glitters Is Sarcoidosis: Septal Perforator Myocardial Infarction Mimicking Isolated Cardiac Sarcoidosis , Circ Cardiovasc Imaging: 2022
Herrmann J, Lenihan D, Armenian S, Barac A, Blaes A, Cardinale D, Carver J, Dent S, Ky B, Lyon AR, López-Fernández T, Fradley MG, Ganatra S, Curigliano G, Mitchell JD, Minotti G, Lang NN, Liu JE, Neilan TG, Nohria A, O'Quinn R, Pusic I, Porter C, Reynolds KL, Ruddy KJ, Thavendiranathan P, Valent P. Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. , European Heart Journal: 2021
Freyer CW, Fradley M, Madnick D, Carver JR, Frey NV, Gill SI, Ky B, Luger SM, Martin ME, McCurdy SR, O'Quinn R, Perl AE, Stadtmauer EA, Loren AW. Characterization of Pericarditis Following Allogeneic Hematopoietic Cell Transplant. , Transplant Cell Ther: 2021
Freyer CW, Fradley M, Madnick D, Carver JR, Frey NV, Gill SI, Ky B, Luger SM, Martin ME, McCurdy SR, O’Quinn R, Perl AE, Stadtmauer EA, Loren AW. Characterization of Pericarditis following Allogeneic Hematopoietic Cell Transplantation. , Transplant Cell Ther.: 2021
Rao VU, Reeves DJ, Chugh AR, O'Quinn R, Fradley MG, Raghavendra M, Dent S, Barac A, Lenihan D Clinical Approach to Cardiovascular Toxicity of Oral Antineoplastic Agents: JACC State-of-the-Art Review. , Journal of the American College of Cardiology, 77(21): 2021,2693-2716
